NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球仿製藥市場:按類型、應用、給藥途徑、分銷渠道-行業分析和 2030 年預測

Generic Drugs Market Research Report: By Type, Application, Route of Administration, Distribution Channel - Global Industry Analysis and Demand Forecast to 2030

出版商 Prescient & Strategic Intelligence Private Limited 商品編碼 1007637
出版日期 內容資訊 英文 203 Pages
商品交期: 2-3個工作天內
價格
全球仿製藥市場:按類型、應用、給藥途徑、分銷渠道-行業分析和 2030 年預測 Generic Drugs Market Research Report: By Type, Application, Route of Administration, Distribution Channel - Global Industry Analysis and Demand Forecast to 2030
出版日期: 2021年03月01日內容資訊: 英文 203 Pages
簡介

2019年全球仿製藥市場規模為2784億美元。預計該市場在 2020 年至 2030 年間將以 10% 的複合年增長率增長,到 2030 年將達到 7860 億美元。這是因為品牌藥品通常價格昂貴,而且很多人在新興市場很難買到。

根據世界衛生組織 (WHO) 的數據,2020 年近 75% 的死亡將歸因於慢性病。其中,死亡率最高的是缺血性心臟病、糖尿病、癌症和中風,這些都是支撐全球仿製藥市場增長的因素。

本報告調查全球仿製藥市場,包括市場規模、預測、機會、增長和製約因素、類型/用途/給藥途徑/分銷渠道/區域市場分析、競爭形勢、主要它提供公司等信息個人資料。

目錄

第 1 章調查背景

  • 調查目的
  • 市場定義
  • 調查範圍
    • 按類型細分市場
    • 按應用細分市場
    • 按管理途徑細分市場
    • 按分銷渠道細分市場
    • 區域市場細分
    • 分析期
    • 市場數據報告單位
  • 主要利益相關者

第 2 章調查方法

  • 二次調查
  • 初步調查
    • 主要調查的受訪者細分
      • 按地區
      • 按行業進入公司
      • 按公司類型
  • 估計市場規模
  • 數據三角剖分
  • 匯率
  • 調查的先決條件

第 3 章執行摘要

第 4 章介紹

  • 市場定義
    • 按類型
      • 簡單
      • 超級
      • 生物仿製藥
    • 按應用程序
      • 神經系統疾病
      • 心臟病
      • 代謝性疾病
      • 傳染病
      • 骨科疾病
      • 呼吸系統疾病
      • 泌尿生殖系統/荷爾蒙失調
      • 其他
    • 按給藥途徑
      • 口服
      • 注射
      • 皮膚
      • 粘膜
      • 吸入
      • 其他
    • 按分銷渠道
      • 間接
      • 直接
  • 市場動態
    • 趨勢
      • 偏好轉向仿製藥
      • 增加產品銷量
      • 合作與聯盟數量增加
      • 併購增加
    • 增長因素
      • 人口老齡化加劇
      • 重磅藥物專利到期
      • 急慢性病患病率增加
      • 增加對生物技術和製藥公司的研發支出
      • 增長因素對市場預測的影響分析
    • 抑制因素
      • 品牌藥的高營銷給仿製藥蒙上了陰影
      • 醫生對品牌藥物的偏好
      • 制約因素對市場預測的影響分析
    • 市場機會
      • 支持仿製藥監管
  • COVID-19 的影響
    • 供給側分析
      • 仿製藥主要生產商和出口商的現狀
      • 鎖定狀態和勞動力可用性
      • 生產場景
      • 仿製藥主要供應商現狀
    • 需求側分析
  • 波特五力分析

第 5 章全球市場規模和預測

  • 按類型
  • 按應用程序
  • 按給藥途徑
  • 按分銷渠道
  • 按地區

第 6 章北美市場規模和預測

  • 按類型
  • 按應用程序
  • 按給藥途徑
  • 按分銷渠道
  • 按國家/地區

第 7 章歐洲市場規模和預測

  • 按類型
  • 按應用程序
  • 按給藥途徑
  • 按分銷渠道
  • 按國家/地區

第 8 章亞太市場規模和預測

  • 按類型
  • 按應用程序
  • 按給藥途徑
  • 按分銷渠道
  • 按國家/地區

第 9 章拉丁美洲市場規模和預測

  • 按類型
  • 按應用程序
  • 按給藥途徑
  • 按分銷渠道
  • 按國家/地區

第 10 章中東和非洲的市場規模和預測

  • 按類型
  • 按應用程序
  • 按給藥途徑
  • 按分銷渠道
  • 按國家/地區

第 11 章競爭形勢

  • 大公司戰略發展
    • 產品發佈和審批
    • 聯盟
  • 主要公司及其產品

第 12 章公司簡介

  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Alkem Laboratories Limited
  • Teva Pharmaceutical Industries Limited
  • Mylan N.V.
  • Lupin Limited
  • Endo International plc
  • Aurobindo Pharma Limited
  • STADA Arzneimittel AG
  • Hikma Pharmaceuticals plc
  • Sawai Pharmaceutical Co. Ltd.
  • Piramal Enterprises Ltd.
  • Mallinckrodt plc
  • Torrent Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals Inc.
  • Taro Pharmaceutical Industries Ltd.
  • Perrigo Company plc
  • Alvogen
  • Nichi-Iko Pharmaceutical Co. Ltd.
  • Glenmark Life Sciences Limited
  • Amphastar Pharmaceuticals Inc.
  • MSN Labs
  • CUSTOPHARM INC.
  • Cadila Healthcare Ltd.
  • Pfizer Inc.
  • Sanofi
  • Bausch Health Companies Inc.

第 13 章附錄

  • 縮寫
  • 來源和參考資料
  • 相關報導
目錄
Product Code: LS12164

Almost 75% of the deaths in 2020 were because of chronic diseases, as per the World Health Organization (WHO). Among the diseases, the deadliest were ischemic heart disease, diabetes, cancer, and stroke. This is to be a major factor to propel the global generic drugs market size to $786.0 billion by 2030 from $278.4 billion in 2019, at a 10.0% CAGR between 2020 and 2030. This is because branded drugs are often expensive, which is why a large number of people in developing countries are not able to purchase them.

Generic drugs, on the other hand, are cost-effective, at the same time contain the same active ingredients and have a similar effect as patented drugs. In this regard, the generic drugs market is also being driven by the patent expiry of blockbuster medications. As patented drugs lose their certification, it gives pharmaceutical companies the opportunity to create their cheaper but equally effective variants.

During the COVID-19 crisis, the generic drugs market has received a boost, as governments around the world, despite implementing lockdowns and movement restrictions, have ensured that the supply of essential medicines isn't hampered. Moreover, as people have lost their jobs or are working at reduced salaries, they are drastically cutting down on expenses, which is why the preference for cheap generic drugs over the expensive patented ones has risen.

In the near future, the highest CAGR in the generic drugs market, of 10.4%, is predicted to be displayed by the oral category, on the basis of route of administration. Being the simplest and a painless method of drug administration, it is widely popular among the masses.

The indirect bifurcation generates the higher revenue in the generic drugs market, under the distribution channel segment. Most people prefer to buy drugs from hospitals, clinics, and pharmacies/chemists, which are all increasing in number around the world due to the mounting patient count.

Asia-Pacific (APAC) has made the largest revenue contribution to the generic drugs market till now, and it will continue doing so throughout this decade. The growing geriatric population and burden of acute and chronic diseases are driving the demand for medication. Moreover, the majority of the people here still cannot afford expensive medicines, which is why they go for the cost-effective generic drugs.

Major global generic drugs market players include Dr. Reddy's Laboratories Ltd., Cipla Ltd., Alkem Laboratories Limited, Mylan N.V., Teva Pharmaceutical Industries Limited, Lupin Limited, Aurobindo Pharma Limited, Endo International plc, STADA Arzneimittel AG, Sawai Pharmaceutical Co. Ltd., Hikma Pharmaceuticals plc, Piramal Enterprises Ltd., Torrent Pharmaceuticals Ltd., Mallinckrodt plc, Amneal Pharmaceuticals Inc., Perrigo Company plc, Taro Pharmaceutical Industries Ltd., Alvogen, Glenmark Life Sciences Limited, Nichi-Iko Pharmaceutical Co. Ltd., Amphastar Pharmaceuticals Inc., CUSTOPHARM INC., MSN Labs, Cadila Healthcare Ltd., Sanofi, Pfizer Inc., and Bausch Health Companies Inc.

Table of Contents

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Market Definition
  • 1.3 Research Scope
    • 1.3.1 Market Segmentation by Type
    • 1.3.2 Market Segmentation by Application
    • 1.3.3 Market Segmentation by Route of Administration
    • 1.3.4 Market Segmentation by Distribution Channel
    • 1.3.5 Market Segmentation by Region
    • 1.3.6 Analysis Period
    • 1.3.7 Market Data Reporting Unit
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 Breakdown of Primary Research Respondents
      • 2.2.1.1 By region
      • 2.2.1.2 By industry participant
      • 2.2.1.3 By company type
  • 2.3 Market Size Estimation
  • 2.4 Data Triangulation
  • 2.5 Currency Conversion Rates
  • 2.6 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

  • 4.1 Market Definition
    • 4.1.1 By Type
      • 4.1.1.1 Simple
      • 4.1.1.2 Super
      • 4.1.1.3 Biosimilars
    • 4.1.2 By Application
      • 4.1.2.1 Neurological diseases
      • 4.1.2.2 Cardiological diseases
      • 4.1.2.3 Metabolic diseases
      • 4.1.2.4 Infectious diseases
      • 4.1.2.5 Orthopedic diseases
      • 4.1.2.6 Respiratory diseases
      • 4.1.2.7 Genitourinary/hormonal diseases
      • 4.1.2.8 Others
    • 4.1.3 By Route of Administration
      • 4.1.3.1 Oral
      • 4.1.3.2 Injection
      • 4.1.3.3 Cutaneous
      • 4.1.3.4 Mucosal
      • 4.1.3.5 Inhalation
      • 4.1.3.6 Others
    • 4.1.4 By Distribution Channel
      • 4.1.4.1 Indirect
      • 4.1.4.2 Direct
  • 4.2 Market Dynamics
    • 4.2.1 Trends
      • 4.2.1.1 Shift in preference toward generic drugs
      • 4.2.1.2 Increasing product launches
      • 4.2.1.3 Rising number of collaborations and partnerships
      • 4.2.1.4 Increasing number of mergers and acquisitions
    • 4.2.2 Drivers
      • 4.2.2.1 Increasing ageing population
      • 4.2.2.2 Patent expiration of blockbuster drugs
      • 4.2.2.3 Growing prevalence of acute and chronic diseases
      • 4.2.2.4 Rising R&D expenditure of biotech and pharma companies
      • 4.2.2.5 Impact analysis of drivers on market forecast
    • 4.2.3 Restraints
      • 4.2.3.1 High marketing of branded drugs overshadows generics
      • 4.2.3.2 Preference of physicians toward branded drugs
      • 4.2.3.3 Impact analysis of restraints on market forecast
    • 4.2.4 Opportunities
      • 4.2.4.1 Supportive regulations for generics
  • 4.3 Impact of COVID-19
    • 4.3.1 Supply Side Analysis
      • 4.3.1.1 Current scenario of major manufactures and exporters of generic products
      • 4.3.1.2 Situation of lockdown and workforce availability
      • 4.3.1.3 Production scenario
      • 4.3.1.4 Situation of major countries supplying generic drugs
    • 4.3.2 Demand Side Analysis
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Intensity of Rivalry
    • 4.4.4 Threat of New Entrants
    • 4.4.5 Threat of Substitutes

Chapter 5. Global Market Size and Forecast

  • 5.1 By Type
  • 5.2 By Application
  • 5.3 By Route of Administration
  • 5.4 By Distribution Channel
  • 5.5 By Region

Chapter 6. North America Market Size and Forecast

  • 6.1 By Type
  • 6.2 By Application
  • 6.3 By Route of Administration
  • 6.4 By Distribution Channel
  • 6.5 By Country

Chapter 7. Europe Market Size and Forecast

  • 7.1 By Type
  • 7.2 By Application
  • 7.3 By Route of Administration
  • 7.4 By Distribution Channel
  • 7.5 By Country

Chapter 8. APAC Market Size and Forecast

  • 8.1 By Type
  • 8.2 By Application
  • 8.3 By Route of Administration
  • 8.4 By Distribution Channel
  • 8.5 By Country

Chapter 9. LATAM Market Size and Forecast

  • 9.1 By Type
  • 9.2 By Application
  • 9.3 By Route of Administration
  • 9.4 By Distribution Channel
  • 9.5 By Country

Chapter 10. MEA Market Size and Forecast

  • 10.1 By Type
  • 10.2 By Application
  • 10.3 By Route of Administration
  • 10.4 By Distribution Channel
  • 10.5 By Country

Chapter 11. Competitive Landscape

  • 11.1 Strategic Developments of Key Players
    • 11.1.1 Product Launches and Approvals
    • 11.1.2 Partnerships
  • 11.2 Major Players and Their Offerings

Chapter 12. Company Profiles

  • 12.1 Cipla Ltd.
    • 12.1.1 Business Overview
    • 12.1.2 Product and Service Offerings
    • 12.1.3 Key Financial Summary
  • 12.2 Dr. Reddy's Laboratories Ltd.
    • 12.2.1 Business Overview
    • 12.2.2 Product and Service Offerings
    • 12.2.3 Key Financial Summary
  • 12.3 Alkem Laboratories Limited
    • 12.3.1 Business Overview
    • 12.3.2 Product and Service Offerings
    • 12.3.3 Key Financial Summary
  • 12.4 Teva Pharmaceutical Industries Limited
    • 12.4.1 Business Overview
    • 12.4.2 Product and Service Offerings
    • 12.4.3 Key Financial Summary
  • 12.5 Mylan N.V.
    • 12.5.1 Business Overview
    • 12.5.2 Product and Service Offerings
    • 12.5.3 Key Financial Summary
  • 12.6 Lupin Limited
    • 12.6.1 Business Overview
    • 12.6.2 Product and Service Offerings
    • 12.6.3 Key Financial Summary
  • 12.7 Endo International plc
    • 12.7.1 Business Overview
    • 12.7.2 Product and Service Offerings
    • 12.7.3 Key Financial Summary
  • 12.8 Aurobindo Pharma Limited
    • 12.8.1 Business Overview
    • 12.8.2 Product and Service Offerings
    • 12.8.3 Key Financial Summary
  • 12.9 STADA Arzneimittel AG
    • 12.9.1 Business Overview
    • 12.9.2 Product and Service Offerings
    • 12.9.3 Key Financial Summary
  • 12.10 Hikma Pharmaceuticals plc
    • 12.10.1 Business Overview
    • 12.10.2 Product and Service Offerings
    • 12.10.3 Key Financial Summary
  • 12.11 Sawai Pharmaceutical Co. Ltd.
    • 12.11.1 Business Overview
    • 12.11.2 Product and Service Offerings
    • 12.11.3 Key Financial Summary
  • 12.12 Piramal Enterprises Ltd.
    • 12.12.1 Business Overview
    • 12.12.2 Product and Service Offerings
    • 12.12.3 Key Financial Summary
  • 12.13 Mallinckrodt plc
    • 12.13.1 Business Overview
    • 12.13.2 Product and Service Offerings
    • 12.13.3 Key Financial Summary
  • 12.14 Torrent Pharmaceuticals Ltd.
    • 12.14.1 Business Overview
    • 12.14.2 Product and Service Offerings
    • 12.14.3 Key Financial Summary
  • 12.15 Amneal Pharmaceuticals Inc.
    • 12.15.1 Business Overview
    • 12.15.2 Product and Service Offerings
    • 12.15.3 Key Financial Summary
  • 12.16 Taro Pharmaceutical Industries Ltd.
    • 12.16.1 Business Overview
    • 12.16.2 Product and Service Offerings
    • 12.16.3 Key Financial Summary
  • 12.17 Perrigo Company plc
    • 12.17.1 Business Overview
    • 12.17.2 Product and Service Offerings
    • 12.17.3 Key Financial Summary
  • 12.18 Alvogen
    • 12.18.1 Business Overview
    • 12.18.2 Product and Service Offerings
  • 12.19 Nichi-Iko Pharmaceutical Co. Ltd.
    • 12.19.1 Business Overview
    • 12.19.2 Product and Service Offerings
    • 12.19.3 Key Financial Summary
  • 12.20 Glenmark Life Sciences Limited
    • 12.20.1 Business Overview
    • 12.20.2 Product and Service Offerings
    • 12.20.3 Key Financial Summary
  • 12.21 Amphastar Pharmaceuticals Inc.
    • 12.21.1 Business Overview
    • 12.21.2 Product and Service Offerings
    • 12.21.3 Key Financial Summary
  • 12.22 MSN Labs
    • 12.22.1 Business Overview
    • 12.22.2 Product and Service Offerings
  • 12.23 CUSTOPHARM INC.
    • 12.23.1 Business Overview
    • 12.23.2 Product and Service Offerings
  • 12.24 Cadila Healthcare Ltd.
    • 12.24.1 Business overview
    • 12.24.2 Product and Service Offerings
    • 12.24.3 Key Financial Summary
  • 12.25 Pfizer Inc.
    • 12.25.1 Business Overview
    • 12.25.2 Product and Service Offerings
    • 12.25.3 Key Financial Summary
  • 12.26 Sanofi
    • 12.26.1 Business Overview
    • 12.26.2 Product and Service Offerings
    • 12.26.3 Key Financial Summary
  • 12.27 Bausch Health Companies Inc.
    • 12.27.1 Business Overview
    • 12.27.2 Product and Service Offerings
    • 12.27.3 Key Financial Summary

Chapter 13. Appendix

  • 13.1 Abbreviations
  • 13.2 Sources and References
  • 13.3 Related Reports

LIST OF TABLES

  • TABLE 1 VALUE MARKET SIZE ANALYSIS PERIOD
  • TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 4 GLOBAL GENERIC DRUGS MARKET, BY TYPE, $B (2014-2019)
  • TABLE 5 GLOBAL GENERIC DRUGS MARKET, BY TYPE, $B (2020-2030)
  • TABLE 6 GLOBAL GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2019)
  • TABLE 7 GLOBAL GENERIC DRUGS MARKET, BY APPLICATION, $B (2020-2030)
  • TABLE 8 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2019)
  • TABLE 9 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020-2030)
  • TABLE 10 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2019)
  • TABLE 11 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020-2030)
  • TABLE 12 GLOBAL GENERIC DRUGS MARKET, BY REGION, $B (2014-2019)
  • TABLE 13 GLOBAL GENERIC DRUGS MARKET, BY REGION, $B (2020-2030)
  • TABLE 14 NORTH AMERICA GENERIC DRUGS MARKET, BY TYPE, $B (2014-2019)
  • TABLE 15 NORTH AMERICA GENERIC DRUGS MARKET, BY TYPE, $B (2020-2030)
  • TABLE 16 NORTH AMERICA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2019)
  • TABLE 17 NORTH AMERICA GENERIC DRUGS MARKET, BY APPLICATION, $B (2020-2030)
  • TABLE 18 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2019)
  • TABLE 19 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020-2030)
  • TABLE 20 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2019)
  • TABLE 21 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020-2030)
  • TABLE 22 NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2019)
  • TABLE 23 NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, $B (2020-2030)
  • TABLE 24 EUROPE GENERIC DRUGS MARKET, BY TYPE, $B (2014-2019)
  • TABLE 25 EUROPE GENERIC DRUGS MARKET, BY TYPE, $B (2020-2030)
  • TABLE 26 EUROPE GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2019)
  • TABLE 27 EUROPE GENERIC DRUGS MARKET, BY APPLICATION, $B (2020-2030)
  • TABLE 28 EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2019)
  • TABLE 29 EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020-2030)
  • TABLE 30 EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2019)
  • TABLE 31 EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020-2030)
  • TABLE 32 EUROPE GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2019)
  • TABLE 33 EUROPE GENERIC DRUGS MARKET, BY COUNTRY, $B (2020-2030)
  • TABLE 34 APAC GENERIC DRUGS MARKET, BY TYPE, $B (2014-2019)
  • TABLE 35 APAC GENERIC DRUGS MARKET, BY TYPE, $B (2020-2030)
  • TABLE 36 APAC GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2019)
  • TABLE 37 APAC GENERIC DRUGS MARKET, BY APPLICATION, $B (2020-2030)
  • TABLE 38 APAC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2019)
  • TABLE 39 APAC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020-2030)
  • TABLE 40 APAC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2019)
  • TABLE 41 APAC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020-2030)
  • TABLE 42 APAC GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2019)
  • TABLE 43 APAC GENERIC DRUGS MARKET, BY COUNTRY, $B (2020-2030)
  • TABLE 44 LATAM GENERIC DRUGS MARKET, BY TYPE, $B (2014-2019)
  • TABLE 45 LATAM GENERIC DRUGS MARKET, BY TYPE, $B (2020-2030)
  • TABLE 46 LATAM GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2019)
  • TABLE 47 LATAM GENERIC DRUGS MARKET, BY APPLICATION, $B (2020-2030)
  • TABLE 48 LATAM GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2019)
  • TABLE 49 LATAM GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020-2030)
  • TABLE 50 LATAM GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2019)
  • TABLE 51 LATAM GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020-2030)
  • TABLE 52 LATAM GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2019)
  • TABLE 53 LATAM GENERIC DRUGS MARKET, BY COUNTRY, $B (2020-2030)
  • TABLE 54 MEA GENERIC DRUGS MARKET, BY TYPE, $B (2014-2019)
  • TABLE 55 MEA GENERIC DRUGS MARKET, BY TYPE, $B (2020-2030)
  • TABLE 56 MEA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2019)
  • TABLE 57 MEA GENERIC DRUGS MARKET, BY APPLICATION, $B (2020-2030)
  • TABLE 58 MEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2019)
  • TABLE 59 MEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020-2030)
  • TABLE 60 MEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2019)
  • TABLE 61 MEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020-2030)
  • TABLE 62 MEA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2019)
  • TABLE 63 MEA GENERIC DRUGS MARKET, BY COUNTRY, $B (2020-2030)
  • TABLE 64 MAJOR PLAYERS AND THEIR OFFERINGS
  • TABLE 65 CIPLA LTD. - AT A GLANCE
  • TABLE 66 CIPLA LTD. - KEY FINANCIAL SUMMARY
  • TABLE 67 DR. REDDY'S LABORATORIES LTD. - AT A GLANCE
  • TABLE 68 DR. REDDY'S LABORATORIES LTD. - KEY FINANCIAL SUMMARY
  • TABLE 69 ALKEM LABORATORIES LIMITED - AT A GLANCE
  • TABLE 70 ALKEM LABORATORIES LIMITED - KEY FINANCIAL SUMMARY
  • TABLE 71 TEVA PHARMACEUTICAL INDUSTRIES LIMITED - AT A GLANCE
  • TABLE 72 TEVA PHARMACEUTICAL INDUSTRIES LIMITED - KEY FINANCIAL SUMMARY
  • TABLE 73 MYLAN N.V. - AT A GLANCE
  • TABLE 74 MYLAN N.V. - KEY FINANCIAL SUMMARY
  • TABLE 75 LUPIN LIMITED - AT A GLANCE
  • TABLE 76 LUPIN LIMITED - KEY FINANCIAL SUMMARY
  • TABLE 77 ENDO INTERNATIONAL PLC - AT A GLANCE
  • TABLE 78 ENDO INTERNATIONAL PLC - KEY FINANCIAL SUMMARY
  • TABLE 79 AUROBINDO PHARMA LIMITED - AT A GLANCE
  • TABLE 80 AUROBINDO PHARMA LIMITED - KEY FINANCIAL SUMMARY
  • TABLE 81 STADA ARZNEIMITTEL AG - AT A GLANCE
  • TABLE 82 STADA ARZNEIMITTEL AG - KEY FINANCIAL SUMMARY
  • TABLE 83 HIKMA PHARMACEUTICALS PLC - AT A GLANCE
  • TABLE 84 HIKMA PHARMACEUTICALS PLC - KEY FINANCIAL SUMMARY
  • TABLE 85 SAWAI PHARMACEUTICAL CO. LTD. - AT A GLANCE
  • TABLE 86 SAWAI PHARMACEUTICAL CO. LTD. - KEY FINANCIAL SUMMARY
  • TABLE 87 PIRAMAL ENTERPRISES LTD. - AT A GLANCE
  • TABLE 88 PIRAMAL ENTERPRISES LTD. - KEY FINANCIAL SUMMARY
  • TABLE 89 MALLINCKRODT PLC - AT A GLANCE
  • TABLE 90 MALLINCKRODT PLC - KEY FINANCIAL SUMMARY
  • TABLE 91 TORRENT PHARMACEUTICALS LTD. - AT A GLANCE
  • TABLE 92 TORRENT PHARMACEUTICALS LTD. - KEY FINANCIAL SUMMARY
  • TABLE 93 AMNEAL PHARMACEUTICALS INC. - AT A GLANCE
  • TABLE 94 AMNEAL PHARMACEUTICALS INC. - KEY FINANCIAL SUMMARY
  • TABLE 95 TARO PHARMACEUTICAL INDUSTRIES LTD. - AT A GLANCE
  • TABLE 96 TARO PHARMACEUTICAL INDUSTRIES LTD. - KEY FINANCIAL SUMMARY
  • TABLE 97 PERRIGO COMPANY PLC - AT A GLANCE
  • TABLE 98 PERRIGO COMPANY PLC - KEY FINANCIAL SUMMARY
  • TABLE 99 ALVOGEN - AT A GLANCE
  • TABLE 100 NICHI-IKO PHARMACEUTICAL CO. LTD. - AT A GLANCE
  • TABLE 101 NICHI-IKO PHARMACEUTICAL CO. LTD. - KEY FINANCIAL SUMMARY
  • TABLE 102 GLENMARK LIFE SCIENCES LIMITED - AT A GLANCE
  • TABLE 103 GLENMARK LIFE SCIENCES LIMITED - KEY FINANCIAL SUMMARY
  • TABLE 104 AMPHASTAR PHARMACEUTICALS INC. - AT A GLANCE
  • TABLE 105 AMPHASTAR PHARMACEUTICALS INC. - KEY FINANCIAL SUMMARY
  • TABLE 106 MSN LABS - AT A GLANCE
  • TABLE 107 CUSTOPHARM INC. - AT A GLANCE
  • TABLE 108 CADILA HEALTHCARE LTD. - AT A GLANCE
  • TABLE 109 CADILA HEALTHCARE LTD. - KEY FINANCIAL SUMMARY
  • TABLE 110 PFIZER INC. - AT A GLANCE
  • TABLE 111 PFIZER INC. - KEY FINANCIAL SUMMARY
  • TABLE 112 SANOFI - AT A GLANCE
  • TABLE 113 SANOFI - KEY FINANCIAL SUMMARY
  • TABLE 114 BAUSCH HEALTH COMPANIES INC. - AT A GLANCE
  • TABLE 115 BAUSCH HEALTH COMPANIES INC. - KEY FINANCIAL SUMMARY

LIST OF FIGURES

  • FIG 1 RESEARCH SCOPE
  • FIG 2 RESEARCH METHODOLOGY
  • FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION
  • FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT
  • FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE
  • FIG 6 DATA TRIANGULATION APPROACH
  • FIG 7 CURRENCY CONVERSION RATES FOR USD (2019)
  • FIG 8 GLOBAL GENERIC DRUGS MARKET SUMMARY
  • FIG 9 BARGAINING POWER OF BUYERS
  • FIG 10 BARGAINING POWER OF SUPPLIERS
  • FIG 11 INTENSITY OF RIVALRY
  • FIG 12 THREAT OF NEW ENTRANTS
  • FIG 13 THREAT OF SUBSTITUTES
  • FIG 14 SNAPSHOT OF GLOBAL GENERIC DRUGS MARKET
  • FIG 15 GLOBAL GENERIC DRUGS MARKET, BY TYPE, $B (2014-2030)
  • FIG 16 GLOBAL GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2030)
  • FIG 17 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2030)
  • FIG 18 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2030)
  • FIG 19 WORLDWIDE MAJOR MARKETS FOR GENERIC DRUGS
  • FIG 20 GLOBAL GENERIC DRUGS MARKET, BY REGION, $B (2014-2030)
  • FIG 21 NORTH AMERICA GENERIC DRUGS MARKET SNAPSHOT
  • FIG 22 NORTH AMERICA GENERIC DRUGS MARKET, BY TYPE, $B (2014-2030)
  • FIG 23 NORTH AMERICA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2030)
  • FIG 24 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2030)
  • FIG 25 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2030)
  • FIG 26 NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2030)
  • FIG 27 EUROPE GENERIC DRUGS MARKET SNAPSHOT
  • FIG 28 EUROPE GENERIC DRUGS MARKET, BY TYPE, $B (2014-2030)
  • FIG 29 EUROPE GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2030)
  • FIG 30 EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2030)
  • FIG 31 EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2030)
  • FIG 32 EUROPE GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2030)
  • FIG 33 APAC GENERIC DRUGS MARKET SNAPSHOT
  • FIG 34 APAC GENERIC DRUGS MARKET, BY TYPE, $B (2014-2030)
  • FIG 35 APAC GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2030)
  • FIG 36 APAC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2030)
  • FIG 37 APAC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2030)
  • FIG 38 APAC GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2030)
  • FIG 39 LATAM GENERIC DRUGS MARKET SNAPSHOT
  • FIG 40 LATAM GENERIC DRUGS MARKET, BY TYPE, $B (2014-2030)
  • FIG 41 LATAM GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2030)
  • FIG 42 LATAM GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2030)
  • FIG 43 LATAM GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2030)
  • FIG 44 LATAM GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2030)
  • FIG 45 MEA GENERIC DRUGS MARKET SNAPSHOT
  • FIG 46 MEA GENERIC DRUGS MARKET, BY TYPE, $B (2014-2030)
  • FIG 47 MEA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2030)
  • FIG 48 MEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2030)
  • FIG 49 MEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2030)
  • FIG 50 MEA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2030)
  • FIG 51 CIPLA LTD. - REVENUE SPLIT BY THERAPY AND GEOGRAPHY (2019)
  • FIG 52 DR. REDDY'S LABORATORIES LTD. - REVENUE SPLIT BY BUSSINESS SEGMENT AND GEOGRAPHY (2019)
  • FIG 53 ALKEM LABORATORIES LIMITED - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 54 TEVA PHARMACEUTICAL INDUSTRIES LIMITED - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 55 MYLAN N.V. - REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2019)
  • FIG 56 LUPIN LIMITED - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
  • FIG 57 ENDO INTERNATIONAL PLC - REVENUE SPLIT BY DIVISION (2019)
  • FIG 58 AUROBINDO PHARMA LIMITED - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 59 STADA ARZNEIMITTEL AG - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 60 HIKMA PHARMACEUTICALS PLC - REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2019)
  • FIG 61 SAWAI PHARMACEUTICAL CO. LTD. - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 62 PIRAMAL ENTERPRISES LTD. - REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2019)
  • FIG 63 MALLINCKRODT PLC - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 64 TORRENT PHARMACEUTICALS LTD. - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 65 AMNEAL PHARMACEUTICALS INC. - REVENUE SPLIT BY SEGMENT (2019)
  • FIG 66 TARO PHARMACEUTICAL INDUSTRIES LTD. - REVENUE SPLIT BY GEOGRAPHY (2020)
  • FIG 67 PERRIGO COMPANY PLC - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 68 NICHI-IKO PHARMACEUTICAL CO. LTD. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 69 GLENMARK LIFE SCIENCES LIMITED - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 70 AMPHASTAR PHARMACEUTICALS INC. - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 71 CADILA HEALTHCARE LTD. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 72 PFIZER INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 73 SANOFI - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 74 BAUSCH HEALTH COMPANIES INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)